{"id":"NCT05161806","sponsor":"Sandoz","briefTitle":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe","officialTitle":"An Open-label, Single-arm, Multicenter Study in Patients With Neovascular Age-related Macular Degeneration to Evaluate the Safety of SOK583A1 (40 mg/mL), a Proposed Aflibercept Biosimilar Product, Provided in a Prefilled Syringe","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-11","primaryCompletion":"2022-05-04","completion":"2022-05-04","firstPosted":"2021-12-17","resultsPosted":"2022-11-18","lastUpdate":"2022-11-18"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-related Macular Degeneration (nAMD)"],"interventions":[{"type":"DRUG","name":"SOK583A1 (40 mg/mL)","otherNames":["aflibercept"]},{"type":"DEVICE","name":"Prefilled Syringe (PFS)","otherNames":[]}],"arms":[{"label":"SOK583A1 (40 mg/mL)","type":"EXPERIMENTAL"}],"summary":"This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.","primaryOutcome":{"measure":"Number of Participants With Ocular Treatment Emergent Adverse Events","timeFrame":"throughout the study, approximately 31 days","effectByArm":[{"arm":"SOK583A1 (40 mg/mL)","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Foreign body sensation in eyes","Intraocular pressure increased","Hypertension","Ocular discomfort"]}}